Compounds for the treatment of oestrogen-dependent illnesses

Bibliography

• PASQUALINI JR, CHETRITE G, NESTOUR EL: Control and expression of oestrone sulphatase activities in human breast cancer. J. Endocrinol. (1996) 150:S99–105.
   PubMedGoogle Scholar
• LI PK, MILANO S, KLUTH L, RHODES ME: Synthesis and sulfatase inhibitory activities of non-steroidal estrone sulfatase inhibitors. J. Steroid Biochem. Mol. Biol. (1996) 59:41–48.
   PubMed Web of Science ®Google Scholar
• LI PK, CHU GH, GUO JP, PETERS A, SELCER KW: Develop-ment of potent non-estrogenic estrone sulfatase inhibitors. Steroids (1998) 63:425–432.
   PubMed Web of Science ®Google Scholar
• WOO LW, HOWARTH NM, PUROHIT A, HEJAZ HA, REED MJ, POTTER BV: Steroidal and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase. J. Med. Chem. (1998) 41:1068–1083.
   PubMed Web of Science ®Google Scholar
• MASAMURA S, ADLERCREUTZ H, HARVEY H et al.: Aromatase inhibitor development for treatment of breast cancer. Breast Cancer Res. Treat. (1995) 33:19–26.
   PubMed Web of Science ®Google Scholar
• SANTNER SJ, SANTEN RJ: Inhibition of estrone sulfatase and 17 beta-hydroxysteroid dehydrogenase by antics-trogens. J. Steroid Biochem. Mol. Biol. (1993) 45:383–390.
   PubMedGoogle Scholar
• HOWARTH NM, PUROHIT A, REED MJ, POTTER BV: Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential. J. Med. Chem. (1994) 37:219–221.
   PubMed Web of Science ®Google Scholar
• PASQUALINI JR, EBERT C, CHETRITE GS: The SEEM: selective estrogen enzyme modulators in breast cancer. Gynecol. Endocrinol (1999) 13 (Supp1.6) :1–8.
   Google Scholar
• BRIGANTI F, SCOZZAFAVA A, SUPURAN CT: Sulfonylamido derivatives of aminoglutethimide and their copper (II) complexes: a novel class of antifungal compounds. Eur. J. Med. Chem. (1997): 32:901–910.
   Web of Science ®Google Scholar
• CHETRITE GS, CORTES-PRIETO J, PHILIPPE JC, WRIGHT F, PASQUALINI JR: Comparison of estrogen concentra-tions, estrone sulfatase and aromatase activities in normal and in cancerous, human breast tissues. J Steroid Biochem. Mot. Biol. (2000) 72:23–27.
   PubMed Web of Science ®Google Scholar
• KOLLI A, CHU GH, RHODES ME, INOUE K, SELCER KW, LI PK: Development of (p-O-sulfamoy1)-N-alkanoyl -phenylalkyl amines as non-steroidal estrone sulfatase inhibitors. J. Steroid Biochem. Mot. Biol. (1999) 68:31–40.
   PubMed Web of Science ®Google Scholar
• PASQUALINI JR, CHETRITE GS: Estrone sulfatase versus estrone sulfotransferase in human breast cancer: potential clinical applications. J Steroid Biochem. Mot. Biol. (1999) 69:287–292.
   PubMed Web of Science ®Google Scholar
• CHU GH, PETERS A, SELCER KW, LI PK: Synthesis and sulfatase inhibitory activities of (E)- and (Z)-4-hydroxytamoxifen sulfamates. Bioorg. Med. Chem. Lett. (1999) 9:141–144.
   PubMed Web of Science ®Google Scholar
• HEJAZ HA, PUROHIT A, MAHON MF, REED MJ, POTTER BV: Synthesis and biological activity of the sup erestrogen (p-17 -oximin o -3-0-sulfam oyl-1,3,5 (10)-estratriene: x-ray crystal structure of (p-17-oximino -3-hydroxy-1,3,5(10)-estratriene. J. Med. Chem. (1999) 42:3188–3192.
   PubMedGoogle Scholar
• AHMED S, JAMES K, SAMPSON L, MASTRI C: Structure-activity relationship study of steroidal and nonster-oidal inhibitors of the enzyme estrone sulfatase. Biochem. Biophys. Res. Commun. (1999) 254:811–815.
   Google Scholar
• WOO LW, HOWARTH NM, PUROHIT A, HEJAZ HA, REED MJ, POTTER BV: Steroidal and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase. J Med. Chem. (1998) 41:1068–1083.
   PubMed Web of Science ®Google Scholar
• ANDERSON C, FREEMAN J, LUCAS LH, FARLEY M, DALHOUMI H, WIDLANSKI TS: Estr one sulfatase: probing structural requirements for substrate and inhibitor recognition. Biochemistry (1997) 36:2586–2594.
   Google Scholar
• OWA T, YOSHINO H, OKAUCHI T et al.: Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. J. Med. Chem. (1999) 42:3789–3799.
   PubMed Web of Science ®Google Scholar
• ••An excellent paper describing a new class of sulphonamidespossessing potent tumour inhibitory properties in vitro and in vivo.
   Google Scholar
• SUPURAN CT, SCOZZAFAVA A: Carbonic anhydrase inhibitors and their therapeutic potential. Exp. Opin. Ther. Patents (2000) 10:575–600.
   Web of Science ®Google Scholar
• •An exhaustive review on the therapeutic and diagnostic applications of the sulphonamide carbonic anhydrase inhibitors, among which their antitumour properties, recently evidenced and investigated in some detail.
   Google Scholar
• SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors. Synthesis of N-Morpholyl-thiocarbonyl-sulfenylamino aromatic/heterocyclic sulfonamides and their interaction with isozymes 1,11 and W. Bioorg. Med. Chem. Lett. (2000) 10:1117–1120.
   Google Scholar
• SUPURAN CT, BRIGANTI F, TILLI S, CHEGWIDDEN WR, SCOZZAFAVA A: Carbonic anhydrase inhibitors. Sulfonamides as antitumor agents ? Bioorg. Med. Chem. (2000) 8: [In Press].
   Google Scholar
• LO YS, NOLAN JC, MAREN TH, WELSTEAD WJ, GRIPSHOVER FF, SHAMBLEE DA: Synthesis and physico-chemical properties of sulfamate derivatives as topical antiglaucoma agents. J Med. Chem. (1992) 35:4790–4794.
   PubMed Web of Science ®Google Scholar
• BRIGANTI F, PIERATTELLI R, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors. Part 37 Novel classes of carbonic anhydrase inhibitors and their interaction with the native and cobalt-substituted enzyme: kinetic and spectroscopic investigations. Eur. J. Med. Chem. (1996) 31:1001–1010.
   Google Scholar
• SCOZZAFAVA A, BANCIU MD, POPESCU A, SUPURAN CT: Carbonic anhydrase inhibitors. Inhibition of isozymes I, II and W by sulfamide and sulfamic acid derivatives. J. Enz. Inhib. (2000) 15:443–453.
   Google Scholar